Press Releases :: XORTX Therapeutics Inc. (XRTX)

Sep 18, 2026 8:05am EDT

XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity

Sep 10, 2026 4:05pm EDT

XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™

Sep 08, 2026 6:15pm EDT

XORTX Re-Engages Investor Relations Program

Aug 28, 2026 7:00am EDT

XORTX Announces Termination and Postponement of Investor Relations Program

Jul 31, 2026 5:00pm EDT

XORTX Announces Director Resignation

Jul 29, 2026 7:00am EDT

XORTX Appoints New Director

Jun 15, 2026 7:00am EDT

XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO

Jun 12, 2026 5:00pm EDT

XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange

May 19, 2026 7:00am EDT

XORTX Announces Closing of US$5 Million Public Offering

May 14, 2026 7:00am EDT

XORTX Announces US$5 Million Public Offering

1
2
3
4
5
6
7
8
9
10
…21
arrow_forward

rss_feed News RSS